^
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: B - Late Trials
    EGFR overexpression
    Esophageal Squamous Cell Carcinoma
    erlotinib
    Sensitive: B - Late Trials
    No biomarker
    Esophageal Squamous Cell Carcinoma
    tislelizumab
    Sensitive: B - Late Trials
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab + ipilimumab
    Sensitive: B - Late Trials
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    tislelizumab
    Sensitive: B - Late Trials
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    sintilimab
    Sensitive: B - Late Trials
    PD-L1 overexpression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive: B - Late Trials
    NTRK3 fusion
    Esophageal Squamous Cell Carcinoma
    larotrectinib
    Sensitive: C1 - Off-label
    NTRK2 fusion
    Esophageal Squamous Cell Carcinoma
    larotrectinib
    Sensitive: C1 - Off-label
    NTRK1 fusion
    Esophageal Squamous Cell Carcinoma
    larotrectinib
    Sensitive: C1 - Off-label
    EGFR mutation
    Esophageal Squamous Cell Carcinoma
    afatinib
    Sensitive: C1 - Off-label
    HER-2 positive
    Esophageal Squamous Cell Carcinoma
    trastuzumab
    Sensitive: C1 - Off-label
    EGFR amplification
    Esophageal Squamous Cell Carcinoma
    afatinib
    Sensitive: C2 – Inclusion Criteria
    EGFR overexpression
    Esophageal Squamous Cell Carcinoma
    Z650
    Sensitive: C2 – Inclusion Criteria
    NRG1 overexpression
    Esophageal Squamous Cell Carcinoma
    AV-203
    Sensitive: C3 – Early Trials
    NDRG1 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Resistant: C3 – Early Trials
    SGK1 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Resistant: C3 – Early Trials
    AFAP1-AS1 overexpression
    Esophageal Squamous Cell Carcinoma
    FP
    Resistant: C3 – Early Trials
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    camrelizumab
    Sensitive: C3 – Early Trials
    TLR signature
    Esophageal Squamous Cell Carcinoma
    tislelizumab
    Sensitive: C3 – Early Trials
    NDRG1-H
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Sensitive: C3 – Early Trials
    DKK1 overexpression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab + DKN-01
    Sensitive: C3 – Early Trials
    DKK1 overexpression
    Esophageal Squamous Cell Carcinoma
    DKN-01
    Sensitive: C3 – Early Trials
    NFKB1 expression
    Esophageal Squamous Cell Carcinoma
    rivoceranib
    Sensitive: C3 – Early Trials
    KDR expression
    Esophageal Squamous Cell Carcinoma
    rivoceranib
    Sensitive: C3 – Early Trials
    PD-L1 overexpression + CCL5 overexpression
    Esophageal Squamous Cell Carcinoma
    Immunotherapy
    Sensitive: C3 – Early Trials
    PD-L1 underexpression
    Esophageal Squamous Cell Carcinoma
    toripalimab + surufatinib
    Sensitive: C3 – Early Trials
    TTN D7145H
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Sensitive: C3 – Early Trials
    MYH4 Q1210fs
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Sensitive: C3 – Early Trials
    MRE11A underexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Resistant: C3 – Early Trials
    UBQLN4 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Resistant: C3 – Early Trials
    PD-L1 overexpression
    Esophageal Squamous Cell Carcinoma
    AB122
    Sensitive: C3 – Early Trials
    TP53 mutation
    Esophageal Squamous Cell Carcinoma
    SCT200
    Sensitive: C3 – Early Trials
    CD44 overexpression + CD24 underexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin + 5-fluorouracil
    Resistant: C3 – Early Trials
    CD73 underexpression
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: C3 – Early Trials
    CD73 underexpression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive: C3 – Early Trials
    PD-L1 overexpression
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: C3 – Early Trials
    CD276 overexpression
    Esophageal Squamous Cell Carcinoma
    DS-7300
    Sensitive: C3 – Early Trials
    EGFR amplification
    Esophageal Squamous Cell Carcinoma
    Z650
    Sensitive: C3 – Early Trials
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    PD1 inhibitor
    Sensitive: C3 – Early Trials
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    toripalimab + surufatinib
    Sensitive: C3 – Early Trials
    BRCA1 mutation
    Esophageal Squamous Cell Carcinoma
    FOLFOX
    Sensitive: C4 – Case Studies
    CDK14 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Resistant: D – Preclinical
    MACC1-AS1 overexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Resistant: D – Preclinical
    PARP1 expression
    Esophageal Squamous Cell Carcinoma
    anlotinib
    Sensitive: D – Preclinical
    TP53 mutation
    Esophageal Squamous Cell Carcinoma
    afatinib
    Sensitive: D – Preclinical
    CD31 expression
    Esophageal Squamous Cell Carcinoma
    anlotinib
    Sensitive: D – Preclinical
    BAX expression
    Esophageal Squamous Cell Carcinoma
    anlotinib
    Sensitive: D – Preclinical
    SOX9 overexpression
    Esophageal Squamous Cell Carcinoma
    nanoparticle albumin-bound rapamycin
    Sensitive: D – Preclinical
    EGFR overexpression
    Esophageal Squamous Cell Carcinoma
    nimotuzumab
    Sensitive: D – Preclinical
    LYPD3 expression
    Esophageal Squamous Cell Carcinoma
    BAY1129980
    Sensitive: D – Preclinical
    PER2 underexpression
    Esophageal Squamous Cell Carcinoma
    cisplatin
    Sensitive: D – Preclinical